Answer
Nivolumab may increase the risk of transplant rejection. Use requires an individual specialist assessment of potential cancer benefit against risk to the graft.
Sources for this answer
- OPDIVO 10 mg/mL concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
- UK GovernmentUK Government · Reputable Web
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.